Tae Hyun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1635412/publications.pdf

Version: 2024-02-01

247 papers 8,056 citations

47006 47 h-index 78 g-index

250 all docs

250 docs citations

250 times ranked

9750 citing authors

#	Article	IF	Citations
1	Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08). Japanese Journal of Clinical Oncology, 2022, 52, 616-622.	1.3	9
2	Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS ONE, 2022, 17, e0265668.	2.5	9
3	Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria. Journal of Liver Cancer, 2022, 22, 63-68.	1.1	2
4	Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04). Cancer Biology and Medicine, 2022, 19, 1-14.	3.0	2
5	Active small bowel sparing in intracavitary brachytherapy for cervical cancer. Japanese Journal of Clinical Oncology, 2022, 52, 266-273.	1.3	O
6	A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute. Cancers, 2022, 14, 2033.	3.7	2
7	Dose Profile Modulation of Proton Minibeam for Clinical Application. Cancers, 2022, 14, 2888.	3.7	2
8	Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Tumori, 2021, 107, 030089162093779.	1.1	5
9	Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology, 2021, 74, 603-612.	3.7	118
10	New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12). Breast Cancer Research and Treatment, 2021, 186, 453-462.	2.5	5
11	Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Frontiers in Oncology, 2021, 11, 646473.	2.8	3
12	Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (Korean Radiation Oncology Group 1612) Journal of Clinical Oncology, 2021, 39, e14008-e14008.	1.6	0
13	Photon Versus Proton Beam Therapy for T1–3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis. Frontiers in Oncology, 2021, 11, 699172.	2.8	6
14	Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data. Radiation Oncology Journal, 2021, 39, 107-112.	1.5	8
15	Treatment outcomes of passive scattering proton beam therapyÂfor stage I non-small cell lung cancer. Radiation Oncology, 2021, 16, 155.	2.7	4
16	Beam Angle Optimization for Double-Scattering Proton Delivery Technique Using an Eclipse Application Programming Interface and Convolutional Neural Network. Frontiers in Oncology, 2021, 11, 707464.	2.8	2
17	Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). European Journal of Cancer, 2021, 157, 31-39.	2.8	5
18	Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model. International Journal of Biological Sciences, 2021, 17, 689-701.	6.4	2

#	Article	IF	CITATIONS
19	RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. Journal of Clinical Medicine, 2021, 10, 4652.	2.4	1
20	Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer. Frontiers in Oncology, 2021, 11, 783327.	2.8	7
21	Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12). Breast, 2021, 60, 272-278.	2.2	1
22	Dosimetric Comparisons between Proton Beam Therapy and Modern Photon Radiation Techniques for Stage I Non-Small Cell Lung Cancer According to Tumor Location. Cancers, 2021, 13, 6356.	3.7	5
23	Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12). Breast, 2020, 49, 41-47.	2.2	16
24	Outcome of breast-conserving treatment for axillary lymph node metastasis from occult breast cancer with negative breast MRI. Breast, 2020, 49, 63-69.	2.2	18
25	Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Scientific Reports, 2020, 10, 21712.	3.3	12
26	Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701). Cancers, 2020, 12, 3261.	3.7	2
27	Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 542.	2.8	22
28	Prognostic significance of smoking and alcohol history in young age oral cavity cancer. Oral Diseases, 2020, 26, 1440-1448.	3.0	10
29	Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). International Journal of Radiation Biology, 2020, 96, 759-766.	1.8	12
30	Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02). Journal of Breast Cancer, 2020, 23, 194.	1.9	9
31	Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea. PLoS ONE, 2020, 15, e0242966.	2.5	6
32	Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. Scientific Reports, 2019, 9, 11770.	3.3	19
33	Consensus Report From the Miami Liver Proton Therapy Conference. Frontiers in Oncology, 2019, 9, 457.	2.8	15
34	Mo1382 – Successful Establishment of Pancreatic Cancer Patient-Derived Orthotopic Xenograft Models Using Eus-Guided Fine-Needle Biopsy Samples. Gastroenterology, 2019, 156, S-758-S-759.	1.3	0
35	Predicting lymph node metastasis in pancreatobiliary cancer with magnetic resonance imaging: A prospective analysis. European Journal of Radiology, 2019, 116, 1-7.	2.6	14
36	The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08). Clinical Breast Cancer, 2019, 19, 345-353.e2.	2.4	13

#	Article	IF	CITATIONS
37	Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?. Cancers, 2019, 11, 230.	3.7	22
38	Comparative clinical evaluation of atlas and deep-learning-based auto-segmentation of organ structures in liver cancer. Radiation Oncology, 2019, 14, 213.	2.7	51
39	Cytopathological results of initial endoscopic ultrasoundâ€guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Cytopathology, 2019, 30, 173-178.	0.7	1
40	Effect of Early Management on Pain and Depression in Patients with Pancreatobiliary Cancer: A Randomized Clinical Trial. Cancers, 2019, 11, 79.	3.7	6
41	Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). Cancer Research and Treatment, 2019, 51, 1589-1599.	3.0	18
42	Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment. Gut and Liver, 2019, 13, 683-689.	2,9	12
43	Tolerance design of patientâ€specific range <scp>QA</scp> using the <scp>DMAIC</scp> framework in proton therapy. Medical Physics, 2018, 45, 520-528.	3.0	1
44	Inhibition of AKT suppresses the initiation and progression of <i>BRCA1</i> -associated mammary tumors. International Journal of Biological Sciences, 2018, 14, 1769-1781.	6.4	11
45	Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation. International Journal of Biological Sciences, 2018, 14, 1755-1768.	6.4	9
46	The Impact of Surgical Timing on Pathologic Tumor Response after Short Course and Long Course Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma. Cancer Research and Treatment, 2018, 50, 1039-1050.	3.0	11
47	Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget, 2018, 9, 4034-4043.	1.8	19
48	Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors. Experimental and Molecular Medicine, 2018, 50, 1-16.	7.7	16
49	Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare. EPMA Journal, 2018, 9, 287-297.	6.1	9
50	Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG) Tj ETQq0 (0 0 <u>7 g</u> BT /C)veglock 10 Tf
51	Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer. International Journal of Clinical Oncology, 2018, 23, 924-929.	2.2	1
52	OC-0161: Patterns of Local Recurrence in Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08). Radiotherapy and Oncology, 2018, 127, S82-S83.	0.6	0
53	Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381878387.	1.9	15
54	Patterns of failure in rectal cancer with positive circumferential resection margin after surgery following preoperative chemoradiation: a propensity score matching analysis. British Journal of Radiology, 2018, 91, 20180143.	2.2	6

#	Article	IF	CITATIONS
55	Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer. Radiation Oncology Journal, 2018, 36, 200-209.	1.5	10
56	Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study. Cancer Research and Treatment, 2018, 50, 506-517.	3.0	3
57	Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea. Cancer Research and Treatment, 2018, 50, 335-344.	3.0	10
58	Proximal Resection Margins: More Prognostic than Distal Resection Margins in Patients Undergoing Hilar Cholangiocarcinoma Resection. Cancer Research and Treatment, 2018, 50, 1106-1113.	3.0	13
59	Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23. Cancer Research and Treatment, 2018, 50, 1316-1323.	3.0	20
60	Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea. Cancer Research and Treatment, 2018, 50, 212-221.	3.0	3
61	Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver International, 2017, 37, 90-100.	3.9	58
62	Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiotherapy and Oncology, 2017, 122, 122-129.	0.6	37
63	Response to Is radiotherapy the best option for treating hepatocellular carcinoma with <scp>PVTT</scp> ?. Liver International, 2017, 37, 308-309.	3.9	1
64	CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid. Oncology Letters, 2017, 13, 2591-2598.	1.8	5
65	All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2327-2339.	2.5	12
66	Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer. Nature Communications, 2017, 8, 15966.	12.8	64
67	A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer. Journal of Breast Cancer, 2017, 20, 340.	1.9	4
68	Selective Radiation Therapy for Ductal Carcinoma <i>In Situ</i> Following Breast-Conserving Surgery According to Age and Margin Width: Korean Radiation Oncology Group 11-04 and 16-02 Studies. Journal of Breast Cancer, 2017, 20, 327.	1.9	5
69	Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget, 2017, 8, 94450-94461.	1.8	15
70	A phase II study of gemcitabine as adjuvant treatment for biliary tract cancer after surgical resection Journal of Clinical Oncology, 2017, 35, 330-330.	1.6	3
71	DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. Oncotarget, 2017, 8, 81394-81404.	1.8	14
72	Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival. Oncotarget, 2017, 8, 112598-112609.	1.8	12

#	Article	IF	Citations
73	Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer. Radiation Oncology Journal, 2017, 35, 241-248.	1.5	8
74	Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Research and Treatment, 2017, 49, 61-69.	3.0	14
75	Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients. Cancer Research and Treatment, 2017, 49, 748-758.	3.0	9
76	Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. Cancer Research and Treatment, 2017, 49, 1022-1032.	3.0	9
77	Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418). Cancer Research and Treatment, 2017, 49, 927-936.	3.0	11
78	Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment. Cancer Research and Treatment, 2016, 48, 1363-1372.	3.0	40
79	Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). PLoS ONE, 2016, 11, e0152642.	2.5	22
80	Caspase-3/7-mediated Cleavage of \hat{l}^2 2-spectrin is Required for Acetaminophen-induced Liver Damage. International Journal of Biological Sciences, 2016, 12, 172-183.	6.4	19
81	Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications. Radiation Oncology Journal, 2016, 34, 193-201.	1.5	8
82	Evaluation of quality of life using a tablet PC-based survey in cancer patients treated with radiotherapy: a multi-institutional prospective randomized crossover comparison of paper and tablet PC-based questionnaires (KROG 12–01). Supportive Care in Cancer, 2016, 24, 4399-4406.	2.2	10
83	Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology, 2016, 16, 1099-1105.	1.1	34
84	Is lateral pelvic node dissection necessary after preoperative chemoradiotherapy for rectal cancer patients with initially suspected lateral pelvic node?. Surgery, 2016, 160, 366-376.	1.9	40
85	Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: A multi-institutional study for optimal surgical timing in rectal cancer. Radiotherapy and Oncology, 2016, 119, 512-518.	0.6	35
86	Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial. Radiotherapy and Oncology, 2016, 120, 383-389.	0.6	23
87	Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2016, 192, 714-721.	2.0	14
88	A treatment planning study of proton arc therapy for para-aortic lymph node tumors: dosimetric evaluation of conventional proton therapy, proton arc therapy, and intensity modulated radiotherapy. Radiation Oncology, 2016, 11, 140.	2.7	11
89	Ablative dose proton beam therapy for stageÂl and recurrent non-small cell lung carcinomas. Strahlentherapie Und Onkologie, 2016, 192, 649-657.	2.0	9
90	Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-institutional retrospective study. Radiotherapy and Oncology, 2016, 118, 387-392.	0.6	14

#	Article	IF	Citations
91	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 612-620.	0.8	49
92	Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer. Cancer Research and Treatment, 2016, 48, 1330-1337.	3.0	45
93	Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features. Oncotarget, 2016, 7, 81888-81898.	1.8	1
94	Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer?. Journal of Surgical Oncology, 2015, 111, 459-464.	1.7	110
95	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2015, 16, 465.	3.4	168
96	Development of Manual Multi-Leaf Collimator for Proton Therapy in National Cancer Center. Progress in Medical Physics, 2015, 26, 250.	0.4	3
97	Postoperative CA19-9 Change Is a Useful Predictor of Intrahepatic Cholangiocarcinoma Survival following Liver Resection. Disease Markers, 2015, 2015, 1-7.	1.3	14
98	Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma. Endocrine-Related Cancer, 2015, 22, 679-686.	3.1	11
99	Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. Oncology, 2015, 89, 345-350.	1.9	14
100	The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer. Annals of Surgical Oncology, 2015, 22, 209-215.	1.5	32
101	Su2026 Efficacy of Pancreatic Enzyme Supplementation Therapy in Patients With Unresectable Pancreatic Cancer. Gastroenterology, 2015, 148, S-578.	1.3	0
102	2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut and Liver, 2015, 9, 267-317.	2.9	167
103	Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2015, 191, 835-844.	2.0	10
104	Postoperative Simultaneous Integrated Boost-Intensity Modulated Radiation Therapy for Patients with Locoregionally Advanced Papillary Thyroid Carcinoma: Preliminary Results of a Phase II Trial and Propensity Score Analysis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1009-1017.	3.6	15
105	Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. Radiotherapy and Oncology, 2015, 116, 202-208.	0.6	25
106	Administration of Radioactive Iodine Therapy Within 1 Year After Total Thyroidectomy Does Not Affect Vocal Function. Journal of Nuclear Medicine, 2015, 56, 1480-1486.	5.0	7
107	Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study. Journal of Neuro-Oncology, 2015, 125, 377-383.	2.9	19
108	Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta Oncológica, 2015, 54, 1827-1832.	1.8	26

#	Article	IF	CITATIONS
109	PR146 LOCOREGIONAL RECURRENCE BY TUMOR BIOLOGY IN BREAST CANCER PATIENTS AFTER PREOPERATIVE CHEMOTHERAPY AND BREAST CONSERVATION TREATMENT. Breast, 2015, 24, S72.	2.2	0
110	Radical prostatectomy versus external beam radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2015, 191, 321-329.	2.0	19
111	Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non–Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score MatchedÂAnalysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 133-139.	0.8	17
112	Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2015, 47, 416-423.	3.0	29
113	The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiation Oncology, 2014, 9, 283.	2.7	32
114	Loss of \hat{l}^22 -spectrin prevents cardiomyocyte differentiation and heart development. Cardiovascular Research, 2014, 101, 39-47.	3.8	28
115	Dosimetric Evaluation of Magnetic Resonance Imaging-Based Intracavitary Brachytherapy for Cervical Cancer. Technology in Cancer Research and Treatment, 2014, 13, 243-251.	1.9	5
116	Feasibility study of using statistical process control to customized quality assurance in proton therapy. Medical Physics, 2014, 41, 092105.	3.0	16
117	Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis <scp>B</scp> virusâ€endemic area. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 820-829.	2.8	44
118	Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02. Radiotherapy and Oncology, 2014, 113, 18-23.	0.6	26
119	A Prospective Phase 2 Multicenter Study for theÂEfficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization inÂUnresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1051-1060.	0.8	32
120	Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?. Radiation Oncology, 2014, 9, 296.	2.7	12
121	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). Radiotherapy and Oncology, 2014, 110, 150-154.	0.6	21
122	The volumetric change and dose-response relationship following hypofractionated proton therapy for chordomas. Acta Oncol \tilde{A}^3 gica, 2014, 53, 563-568.	1.8	8
123	Longâ€ŧerm outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. Liver International, 2014, 34, 1278-1286.	3.9	7
124	Efficacy of argon plasma coagulation in the treatment of radiation-induced hemorrhagic gastroduodenal vascular ectasia. Scandinavian Journal of Gastroenterology, 2014, 49, 238-245.	1.5	6
125	Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlentherapie Und Onkologie, 2014, 190, 806-814.	2.0	75
126	Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2014, 190, 882-890.	2.0	29

#	Article	IF	CITATIONS
127	Risk Factors for Recurrence After Therapeutic Lateral Neck Dissection for Primary Papillary Thyroid Cancer. Annals of Surgical Oncology, 2014, 21, 1884-1890.	1.5	48
128	Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer Beneficial?: A Multi-institutional Propensity-Score Matched Analysis. International Journal of Radiation Oncology Biology Physics, 2014, 90, S654.	0.8	2
129	A Prospective Phase II Multicenter Study for the Efficacy of Radiotherapy Following Incomplete Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S50-S51.	0.8	0
130	Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 405-416.	7.7	16
131	Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. Cancer Research and Treatment, 2014, 46, 348-357.	3.0	12
132	Carbohydrate Antigen 19-9 Levels Associated with Pathological Responses to Preoperative Chemoradiotherapy in Rectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5383-5387.	1.2	6
133	Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiation Oncology, 2013, 8, 160.	2.7	11
134	Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy. Radiation Oncology, 2013, 8, 114.	2.7	27
135	A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy. Radiation Oncology, 2013, 8, 28.	2.7	14
136	Comparison of uncovered and covered stents for the treatment of malignant duodenal obstruction caused by pancreaticobiliary cancer. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 2031-2039.	2.4	36
137	Prognostic Value of Gross Tumor Volume for Definitive Radiation Therapy in Patients With Locoregionally Recurrent Non–Small-Cell Lung Cancer After Surgical Resection. Clinical Lung Cancer, 2013, 14, 399-406.	2.6	18
138	Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 87, 690-696.	0.8	157
139	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiation Oncology, 2013, 8, 292.	2.7	57
140	Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan. Radiation Oncology, 2013, 8, 258.	2.7	11
141	Lack of Either Estrogen or Progesterone Receptor Expression Is Associated with Poor Survival Outcome among Luminal A Breast Cancer Subtype. Annals of Surgical Oncology, 2013, 20, 1505-1513.	1.5	31
142	Appropriate indications of initial endoscopic ultrasound evaluation for detecting mural nodules in branch duct intraductal papillary mucinous neoplasms of the pancreas. Scandinavian Journal of Gastroenterology, 2013, 48, 610-616.	1.5	9
143	Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis of >1000 Patients. International Journal of Radiation Oncology Biology Physics, 2013, 87, S3-S4.	0.8	0
144	Feasibility study of glass dosimeter for postal dose intercomparison of high-energy proton therapy beams. Radiation Measurements, 2013, 59, 66-72.	1.4	5

#	Article	IF	CITATIONS
145	Extent of thyroidectomy affects vocal and throat functions: A prospective observational study of lobectomy versus total thyroidectomy. Surgery, 2013, 154, 611-620.	1.9	72
146	Phase II trial of proton beam accelerated partial breast irradiation in breast cancer. Radiotherapy and Oncology, 2013, 108, 209-214.	0.6	56
147	A Model to Estimate the Risk of Breast Cancer-Related Lymphedema: Combinations of Treatment-Related Factors of the Number of Dissected Axillary Nodes, Adjuvant Chemotherapy, and Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 498-503.	0.8	82
148	Preoperative Short-Course Concurrent Chemoradiation Therapy Followed by Delayed Surgery for Locally Advanced Rectal Cancer: A Phase 2 Multicenter Study (KROG 10-01). International Journal of Radiation Oncology Biology Physics, 2013, 86, 34-39.	0.8	39
149	Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2013, 85, 444-450.	0.8	545
150	A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol \tilde{A}^3 gica, 2013, 52, 477-485.	1.8	30
151	Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study. Chemotherapy, 2013, 59, 232-238.	1.6	28
152	Compensation method for respiratory motion in proton treatment planning for mobile liver cancer. Journal of Applied Clinical Medical Physics, 2013, 14, 102-114.	1.9	3
153	Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study. Journal of Korean Medical Science, 2013, 28, 247.	2.5	29
154	Combined Primary Tumor and Extracranial Metastasis Status as Constituent Factor of Prognostic Indices for Predicting the Overall Survival in Patients with Brain Metastases. Journal of Korean Medical Science, 2013, 28, 205.	2.5	4
155	Reappraisal of Pretreatment Carcinoembryonic Antigen in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. Tumori, 2013, 99, 93-99.	1.1	13
156	Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy. Tumori, 2013, 99, 93-9.	1.1	12
157	Association Between a Close Distal Resection Margin and Recurrence After a Sphincter-Saving Resection for T3 Mid- or Low-Rectal Cancer Without Radiotherapy. Annals of Coloproctology, 2013, 29, 231.	2.0	7
158	Volumetric Response Evaluation after Intensity Modulated Radiotherapy in Patients with Supratentorial Gliomas. Technology in Cancer Research and Treatment, 2012, 11, 41-48.	1.9	2
159	Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients. Japanese Journal of Clinical Oncology, 2012, 42, 995-1001.	1.3	4
160	Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer. Oncology, 2012, 83, 83-90.	1.9	46
161	Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study. Chemotherapy, 2012, 58, 225-232.	1.6	18
162	Clinical Significance of Portal-Superior Mesenteric Vein Resection in Pancreatoduodenectomy for Pancreatic Head Cancer. Pancreas, 2012, 41, 102-106.	1.1	47

#	Article	IF	Citations
163	Multiple Primary Malignant Neoplasms in Pancreatic Cancer Patients. Pancreas, 2012, 41, 648-649.	1.1	3
164	Surgical outcome of pancreatic cancer using radical antegrade modular pancreatosplenectomy procedure. World Journal of Gastroenterology, 2012, 18, 5595.	3.3	21
165	Stage-to-Stage Comparison of Preoperative and Postoperative Chemoradiotherapy for T3 Mid or Distal Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 856-862.	0.8	18
166	Tumor Volume Reduction Rate After Preoperative Chemoradiotherapy as a Prognostic Factor in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e193-e199.	0.8	52
167	Phase 3 Trial of Postoperative Chemotherapy Alone Versus Chemoradiation Therapy in Stage III-IV Gastric Cancer Treated With RO Gastrectomy and D2 Lymph Node Dissection. International Journal of Radiation Oncology Biology Physics, 2012, 84, e585-e592.	0.8	94
168	No correlation between pretreatment serum CEA levels and tumor volume in locally advanced rectal cancer patients. Clinica Chimica Acta, 2012, 413, 511-515.	1.1	4
169	T-category reflects the histopathologic characteristics of gallbladder cancer. European Journal of Surgical Oncology, 2012, 38, 537-542.	1.0	5
170	Lymph node ratio is an independent prognostic factor in patients with rectal cancer treated with preoperative chemoradiotherapy and curative resection. European Journal of Surgical Oncology, 2012, 38, 478-483.	1.0	30
171	Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules. Journal of Korean Medical Science, 2012, 27, 1014.	2.5	63
172	Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy?. Cancer, 2012, 118, 4961-4968.	4.1	25
173	CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e743-e748.	0.8	32
174	Locoregional Recurrence of Breast Cancer in Patients Treated With Breast Conservation Surgery and Radiotherapy Following Neoadjuvant Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e697-e705.	0.8	28
175	Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e853-e859.	0.8	71
176	The Effect of a Contrast Agent on Proton Beam Range in Radiotherapy Planning Using Computed Tomography for Patients With Locoregionally Advanced Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e317-e324.	0.8	12
177	Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e623-e630.	0.8	19
178	Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1612-1618.	2.8	28
179	Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. Breast Cancer Research and Treatment, 2011, 126, 779-789.	2.5	13
180	Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer. Radiation Oncology, 2011, 6, 51.	2.7	25

#	Article	IF	Citations
181	Transforming growth factor- \hat{l}^2 adaptor, \hat{l}^2 2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology, 2011, 53, 1676-1684.	7.3	49
182	In Vivo Radiobiological Characterization of Proton Beam at the National Cancer Center in Korea: Effect of the Chk2 Mutation. International Journal of Radiation Oncology Biology Physics, 2011, 79, 559-562.	0.8	17
183	Pathologic Complete Response of Primary Tumor Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. Annals of Surgery, 2010, 252, 998-1004.	4.2	164
184	Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. Radiotherapy and Oncology, 2010, 97, 307-311.	0.6	27
185	Tumor Volume Reduction Rate Measured by Magnetic Resonance Volumetry Correlated With Pathologic Tumor Response of Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 164-171.	0.8	78
186	Adjuvant chemoradiation therapy in gallbladder cancer. Journal of Surgical Oncology, 2010, 102, 87-93.	1.7	55
187	The role of omental flap transposition in patients with locoregional recurrent rectal cancer treated with reirradiation. Journal of Surgical Oncology, 2010, 102, 789-795.	1.7	15
188	Pathologic Nodal Classification Is the Most Discriminating Prognostic Factor for Disease-Free Survival in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy and Curative Resection. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1158-1165.	0.8	86
189	Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in Patients With High-Grade Gliomas. International Journal of Radiation Oncology Biology Physics, 2010, 78, 390-397.	0.8	54
190	Treatment-Related Pneumonitis and Acute Esophagitis in Non–Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 651-658.	0.8	74
191	The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. Radiation Oncology, 2010, 5, 69.	2.7	29
192	Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction. Radiation Oncology, 2010, 5, 97.	2.7	15
193	Local Excision Following Pre-operative Chemoradiotherapy-induced Downstaging for Selected cT3 Distal Rectal Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 754-760.	1.3	22
194	Radiation Pneumonitis after Adjuvant Radiotherapy for Breast Cancer: A Volumetric Analysis Using CT Simulator. Journal of Breast Cancer, 2009, 12, 73.	1.9	4
195	Characteristics of Movement-Induced Dose Reduction in Target Volume: A Comparison Between Photon and Proton Beam Treatment. Medical Dosimetry, 2009, 34, 191-201.	0.9	10
196	A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver International, 2009, 29, 147-152.	3.9	65
197	Dosimetric comparison of four different external beam partial breast irradiation techniques: Three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiotherapy and Oncology, 2009, 90, 66-73.	0.6	135
198	Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine. Journal of Cancer Research and Clinical Oncology, 2008, 134, 397-404.	2.5	5

#	Article	IF	Citations
199	SMART (Simultaneous Modulated Accelerated RadioTherapy) for locally advanced nasopharyngeal carcinomas. Head and Neck, 2008, 30, 159-169.	2.0	22
200	Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology, 2008, 48, 1128-1137.	7.3	63
201	Influence of Lipiodol Agent on Proton Beam Range in Radiotherapy Planning Using Computed Tomography for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, 687-694.	0.8	10
202	In Reply to Dr. Cheng. International Journal of Radiation Oncology Biology Physics, 2008, 71, 961-962.	0.8	0
203	Lateral Lymph Node Metastasis Is a Major Cause of Locoregional Recurrence in Rectal Cancer Treated with Preoperative Chemoradiotherapy and Curative Resection. Annals of Surgical Oncology, 2008, 15, 729-737.	1.5	266
204	Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus–endemic area. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 467-473.	2.8	109
205	Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Research, 2008, 10, R20.	5.0	193
206	Computerized tomography-based quality assurance tool for proton range compensators. Medical Physics, 2008, 35, 3511-3517.	3.0	11
207	The Current Status of Endoscopic Thyroidectomy in Korea. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2008, 18, 231-235.	0.8	24
208	Radiobiological Characterization of Proton Beam at the National Cancer Center in Korea. Journal of Radiation Research, 2008, 49, 509-515.	1.6	19
209	Allogeneic Blood Transfusion Given Before Radiotherapy Is Associated with the Poor Clinical Outcome in Patients with Cervical Cancer. Yonsei Medical Journal, 2008, 49, 993.	2.2	11
210	Primary Malignant Teratoma with a Primitive Neuroectodermal Tumor Component in Thyroid Gland: A Case Report. Journal of Korean Medical Science, 2007, 22, 568.	2.5	21
211	Dose–volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 67, 225-231.	0.8	138
212	Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 378-384.	0.8	90
213	Hepatitis B Virus Reactivation After Three-Dimensional Conformal Radiotherapy in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 813-819.	0.8	93
214	Clinical Parameters Predicting Pathologic Tumor Response After Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1167-1172.	0.8	112
215	Lateral Lymph Node Metastasis Is a Major Cause of Locoregional Recurrence in Rectal Cancer Treated With Preoperative Chemoradiotherapy and Curative Resection. International Journal of Radiation Oncology Biology Physics, 2007, 69, S269.	0.8	0
216	Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Science, 2007, 98, 329-333.	3.9	50

#	Article	IF	Citations
217	Intensity-modulated radiotherapy with a belly board for rectal cancer. International Journal of Colorectal Disease, 2007, 22, 373-379.	2.2	43
218	Optimized matching of film dosimetry with calculated doses for IMRT quality assurance. Physica Medica, 2007, 23, 49-57.	0.7	6
219	Dosimetric Verification of Dynamic Conformal Arc Radiotherapy using the Optimization Algorithm. , 2007, , 1804-1807.		0
220	A new index of the dose homogeneity for treatment planning. , 2007, , 2043-2046.		0
221	Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3cm of the anal verge. European Journal of Surgical Oncology, 2006, 32, 162-167.	1.0	42
222	Three-Dimensional Conformal Radiotherapy of Unresectable Hepatocellular Carcinoma Patients for Whom Transcatheter Arterial Chemoembolization Was Ineffective or Unsuitable. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 568-575.	1.3	105
223	A new evaluation method of target volume coverage and homogeneity for IMRT treatment planning. Physica Medica, 2006, 22, 43-51.	0.7	1
224	The Effect of Belly Board Location in Rectal Cancer Patients Treated with Preoperative Radiotherapy. Clinical Oncology, 2006, 18, 441-446.	1.4	15
225	CT-guided intracavitary radiotherapy for cervical cancer: Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose–volume parameters. International Journal of Radiation Oncology Biology Physics, 2006, 64, 197-204.	0.8	86
226	Geometric shifting of the porta hepatis during posthepatectomy radiotherapy for biliary tract cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 212-216.	0.8	1
227	Preoperative Chemoradiotherapy with Concomitant Small Field Boost Irradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Phase II Study (KROG 04-01). Diseases of the Colon and Rectum, 2006, 49, 1684-1691.	1.3	13
228	Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. Journal of Cancer Research and Clinical Oncology, 2006, 132, 302-308.	2.5	56
229	Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: From diagnosis to prognosis. Gynecologic Oncology, 2006, 103, 165-170.	1.4	65
230	lonizing radiation induces astrocyte gliosis through microglia activation. Neurobiology of Disease, 2006, 21, 457-467.	4.4	179
231	Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?. Cancer, 2006, 106, 1694-1700.	4.1	75
232	Dominant-negative Rac increases both inherent and ionizing radiation-induced cell migration in C6 rat glioma cells. International Journal of Cancer, 2006, 118, 2056-2063.	5.1	37
233	Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer. Cancer Research and Treatment, 2006, 38, 84.	3.0	13
234	SU-FF-T-59: A Simple Scoring Method of Dose Homogeneity for IMRT Treatment Planning. Medical Physics, 2006, 33, 2062-2062.	3.0	0

#	Article	IF	CITATIONS
235	Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 761-768.	0.8	106
236	Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients. International Journal of Radiation Oncology Biology Physics, 2005, 62, 769-775.	0.8	72
237	Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 995-1002.	0.8	79
238	Threeâ€dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer, 2005, 103, 2419-2426.	4.1	172
239	Dosimetric parameters that predict late rectal complications after curative radiotherapy in patients with uterine cervical carcinoma. Cancer, 2005, 104, 1304-1311.	4.1	27
240	Comparative Analysis of the Effects of Belly Board and Bladder Distension in Postoperative Radiotherapy of Rectal Cancer Patients. Strahlentherapie Und Onkologie, 2005, 181, 601-605.	2.0	29
241	Dose-volumetric Parameters for Predicting Severe Radiation Pneumonitis after Three-dimensional Conformal Radiation Therapy for Lung Cancer. Radiology, 2005, 235, 208-215.	7.3	128
242	SU-FF-T-157: Optimal Matching of 3D Film Dosimetry with Calculated Dose for IMRT Quality Assurance. Medical Physics, 2005, 32, 1986-1986.	3.0	0
243	Use of the Rectal Retractor to Reduce the Rectal Dose in High Dose Rate Intracavitary Brachytherapy for a Carcinoma of the Uterine Cervix. Yonsei Medical Journal, 2004, 45, 113.	2.2	10
244	LY294002 inhibits interferon-gamma-stimulated inducible nitric oxide synthase expression in BV2 microglial cells. Biochemical and Biophysical Research Communications, 2004, 318, 691-697.	2.1	26
245	Value of external irradiation for locally advanced papillary thyroid cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1006-1012.	0.8	73
246	Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma. Cancer Research and Treatment, 1970, 47, 34-45.	3.0	54
247	Randomized multicenter phase <scp>II</scp> trial of prophylactic irradiation of paraâ€aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group () Tj ETQq1 1	0.7 &4 314	rg ® T /Overlo